ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection (Q46787103)

25 December 2017

title

ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection (English)

1 reference

25 December 2017

9

James P Allison

0 references

Thomas Pertel

object named as

Thomas Pertel

4

0 references

author name string

Todd C Metzger

1

1 reference

25 December 2017

Hua Long

2

1 reference

25 December 2017

Shobha Potluri

3

1 reference

25 December 2017

Samantha L Bailey-Bucktrout

5

1 reference

25 December 2017

John C Lin

6

1 reference

25 December 2017

Tihui Fu

7

1 reference

25 December 2017

Padmanee Sharma

8

1 reference

25 December 2017

Reid M R Feldman

10

1 reference

25 December 2017

language of work or name

English

0 references

publication date

4 May 2016

1 reference

25 December 2017

published in

Cancer Research

1 reference

25 December 2017

volume

76

1 reference

25 December 2017

page(s)

3684-3689

1 reference

25 December 2017

issue

13

1 reference

25 December 2017

ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

cites work

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

ICOS co-stimulatory receptor is essential for T-cell activation and function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS).

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

ICOS is essential for effective T-helper-cell responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

T-cell co-stimulation through B7RP-1 and ICOS

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Costimulation of CD8 T cell responses by OX40.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Enhancement of CD8+ T cell responses by ICOS/B7h costimulation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

ICOS controls the pool size of effector-memory and regulatory T cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-15-3412

Identifiers

DOI

10.1158/0008-5472.CAN-15-3412

1 reference

25 December 2017

PubMed ID

27197182

1 reference

25 December 2017